IQVIA Holdings Inc. (0JDM.L)
USD 149.37
(4.18%)
USD 149.37
(4.18%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 12.85 Billion USD | 8.99% |
| 2022 | 11.79 Billion USD | 6.53% |
| 2021 | 11.07 Billion USD | -0.16% |
| 2020 | 11.09 Billion USD | -1.02% |
| 2019 | 11.2 Billion USD | 10.76% |
| 2018 | 10.11 Billion USD | 9.17% |
| 2017 | 9.26 Billion USD | 54.38% |
| 2016 | 6 Billion USD | 302.64% |
| 2015 | 1.49 Billion USD | 4.54% |
| 2014 | 1.42 Billion USD | 12.47% |
| 2013 | 1.26 Billion USD | -31.62% |
| 2012 | 1.85 Billion USD | 27.39% |
| 2011 | 1.45 Billion USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 12.29 Billion USD | -4.35% |
| 2024 Q3 | 11.94 Billion USD | 1.87% |
| 2024 Q2 | 11.9 Billion USD | -3.18% |
| 2023 Q2 | 12.63 Billion USD | 5.86% |
| 2023 Q4 | 12.85 Billion USD | 1.83% |
| 2023 FY | 12.85 Billion USD | 8.99% |
| 2023 Q3 | 12.62 Billion USD | -0.1% |
| 2023 Q1 | 11.93 Billion USD | 1.2% |
| 2022 FY | 11.79 Billion USD | 6.53% |
| 2022 Q3 | 11.37 Billion USD | -2.11% |
| 2022 Q1 | 11.56 Billion USD | 4.41% |
| 2022 Q2 | 11.62 Billion USD | 0.55% |
| 2022 Q4 | 11.79 Billion USD | 3.66% |
| 2021 Q1 | 10.27 Billion USD | -7.32% |
| 2021 FY | 11.07 Billion USD | -0.16% |
| 2021 Q2 | 10.82 Billion USD | 5.32% |
| 2021 Q4 | 11.07 Billion USD | 0.43% |
| 2021 Q3 | 11.02 Billion USD | 1.85% |
| 2020 Q3 | 11.26 Billion USD | -1.21% |
| 2020 Q4 | 11.09 Billion USD | -1.53% |
| 2020 Q1 | 11.47 Billion USD | 2.39% |
| 2020 Q2 | 11.4 Billion USD | -0.63% |
| 2020 FY | 11.09 Billion USD | -1.02% |
| 2019 Q4 | 11.2 Billion USD | 1.19% |
| 2019 Q3 | 11.07 Billion USD | 1.96% |
| 2019 Q2 | 10.85 Billion USD | 1.0% |
| 2019 Q1 | 10.75 Billion USD | 6.29% |
| 2019 FY | 11.2 Billion USD | 10.76% |
| 2018 Q1 | 9.48 Billion USD | 2.37% |
| 2018 FY | 10.11 Billion USD | 9.17% |
| 2018 Q4 | 10.11 Billion USD | 3.31% |
| 2018 Q3 | 9.79 Billion USD | -0.58% |
| 2018 Q2 | 9.84 Billion USD | 3.83% |
| 2017 FY | 9.26 Billion USD | 54.38% |
| 2017 Q1 | 7.48 Billion USD | 24.68% |
| 2017 Q3 | 8.65 Billion USD | 7.47% |
| 2017 Q4 | 9.26 Billion USD | 7.11% |
| 2017 Q2 | 8.05 Billion USD | 7.58% |
| 2016 Q1 | 1.4 Billion USD | -5.82% |
| 2016 FY | 6 Billion USD | 302.64% |
| 2016 Q4 | 6 Billion USD | 389.58% |
| 2016 Q3 | 1.22 Billion USD | -17.76% |
| 2016 Q2 | 1.49 Billion USD | 6.18% |
| 2015 Q2 | 1.68 Billion USD | 11.27% |
| 2015 Q1 | 1.51 Billion USD | 6.25% |
| 2015 FY | 1.49 Billion USD | 4.54% |
| 2015 Q4 | 1.49 Billion USD | 6.72% |
| 2015 Q3 | 1.39 Billion USD | -17.15% |
| 2014 Q4 | 1.42 Billion USD | 1.98% |
| 2014 Q2 | 1.41 Billion USD | 8.1% |
| 2014 Q1 | 1.3 Billion USD | 2.96% |
| 2014 FY | 1.42 Billion USD | 12.47% |
| 2014 Q3 | 1.39 Billion USD | -0.92% |
| 2013 Q1 | 1.93 Billion USD | 4.37% |
| 2013 Q2 | 1.45 Billion USD | -24.58% |
| 2013 Q3 | 1.43 Billion USD | -1.59% |
| 2013 FY | 1.26 Billion USD | -31.62% |
| 2013 Q4 | 1.26 Billion USD | -11.73% |
| 2012 FY | 1.85 Billion USD | 27.39% |
| 2012 Q4 | 1.85 Billion USD | 0.0% |
| 2011 FY | 1.45 Billion USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| uniQure N.V. | -102.95 Million USD | 12586.523% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | -6390.294% |
| Dynavax Technologies Corporation | 106.63 Million USD | -11955.141% |
| Illumina, Inc. | 1.21 Billion USD | -958.896% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | -7150.423% |
| Thermo Fisher Scientific Inc. | 26.84 Billion USD | 52.105% |
| Biogen Inc. | 6.28 Billion USD | -104.427% |
| Agios Pharmaceuticals, Inc. | -31.21 Million USD | 41279.486% |
| bluebird bio, Inc. | 108.57 Million USD | -11740.178% |
| Imunon, Inc. | -4.69 Million USD | 273652.952% |
| Mettler-Toledo International Inc. | 2.09 Billion USD | -512.738% |
| Myriad Genetics, Inc. | 88.1 Million USD | -14491.373% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | -1227.477% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 38442.232% |
| Nektar Therapeutics | 210.24 Million USD | -6014.441% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 142679.858% |
| Perrigo Company plc | 3.32 Billion USD | -286.954% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | -40216.763% |
| Editas Medicine, Inc. | -87.11 Million USD | 14856.187% |
| Verastem, Inc. | -37.27 Million USD | 34584.146% |
| Walgreens Boots Alliance, Inc. | 8.23 Billion USD | -56.102% |
| Waters Corporation | 1.96 Billion USD | -555.721% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | -184384.211% |
| Iovance Biotherapeutics, Inc. | -113.88 Million USD | 11387.405% |
| Heron Therapeutics, Inc. | 145.07 Million USD | -8760.873% |
| Unity Biotechnology, Inc. | 7.18 Million USD | -178764.617% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | -3294.077% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | 181156.338% |
| Evolus, Inc. | 63.7 Million USD | -20078.0% |
| Adicet Bio, Inc. | -142 Million USD | 9152.307% |
| Aclaris Therapeutics, Inc. | -36.8 Million USD | 35028.269% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 47535.424% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | -2702.491% |
| FibroGen, Inc. | 56.76 Million USD | -22545.199% |
| Agilent Technologies, Inc. | 1.14 Billion USD | -1022.707% |
| OPKO Health, Inc. | 230.68 Million USD | -5472.582% |
| Homology Medicines, Inc. | 18.43 Million USD | -69623.925% |
| Geron Corporation | 14.76 Million USD | -86987.596% |
| Alnylam Pharmaceuticals, Inc. | 1.58 Billion USD | -710.874% |
| Exelixis, Inc. | -73.05 Million USD | 17697.536% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 23793.232% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 8611.892% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 11639.29% |
| Zoetis Inc. | 4.76 Billion USD | -169.95% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 6533.258% |
| Abeona Therapeutics Inc. | -10.07 Million USD | 127743.73% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 234.412% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 88317.129% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | -1119.324% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 9594.092% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | -830.929% |
| Blueprint Medicines Corporation | 702.83 Million USD | -1729.018% |
| Insmed Incorporated | 721.62 Million USD | -1681.408% |
| TG Therapeutics, Inc. | 17.86 Million USD | -71868.425% |
| Incyte Corporation | -3.17 Billion USD | 504.871% |
| Emergent BioSolutions Inc. | 765.8 Million USD | -1578.637% |